June 7, 2019, by NCI Staff Smoldering myeloma is a slow-growing type of multiple myeloma, a form of cancer in which abnormal plasma cells (purple) make too much of a single type […]
JUNE 4, 2019 NFCR WRITER DAVID PERRY BLOG Ask any parent about their child fighting cancer and words like “nightmare” and “helpless” will almost certainly be part of the conversation. Within pediatric cancer medicine, the […]
Dr. Christopher Schaber, President and CEO of Soligenix, a company developing drug therapies in rare diseases and areas of unmet medical need, including a treatment for oral mucositis in head and neck […]
The latest Annual Report to the Nation on the Status of Cancer finds that, for all cancer sites combined, cancer death rates continued to decline in men, women, and children in the […]
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is currently an unmet medical need. Soligenix is a biotherapeutic business segment dedicated to […]
New findings from a study by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, show that U.S. incidence rates for aggressive subtypes of uterine cancer rose […]
The Cancer Progress Report delivers crisp headlines of progress at emerging companies developing, in many cases, breakthroughs. It is a fast and efficient must read for anyone serious in the field. For […]
A new diagnostic technology can predict how patients will respond different drugs or drug combinations before the patients take the drugs. Overview Travera is using a breakthrough technology to measure which cancer […]
